STEMVAC vaccine with pembrolizumab for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a cancer vaccine called STEMVAC for people with advanced non-small cell lung cancer. The vaccine is given along with ongoing maintenance immunotherapy (pembrolizumab) to see if it can help keep the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV non-small cell lung cancer that has spread but hasn't progressed after 3–4 cycles of chemotherapy and immunotherapy (including pembrolizumab).
- You have at least one tumor that can be biopsied during treatment, and one or more tumors that can be measured on scans.
- Your general health is good (ECOG score 0 or 1) and estimated survival is over 6 months.
- You are willing to undergo two tumor biopsies during the study and use effective birth control if applicable.
- You have adequate blood counts, kidney and liver function, and no major heart problems or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized (“adaptive”) radiation plan combined with pembrolizumab, and possibly chemotherapy, for advanced stage IV lung cancer. It aims to improve cancer control while carefully managing side effects, including in patients with certain brain metastases.
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
This trial tests a cancer vaccine called STEMVAC combined with chemotherapy in people with a type of breast cancer that has spread and does not have certain markers. The goal is to see if adding the vaccine helps the chemotherapy work better.
This trial tests a vaccine called STEMVAC to see if it can help people with triple-negative breast cancer who still have moderate or large amounts of cancer after chemotherapy. The vaccine is designed to help the immune system fight any remaining cancer cells and improve survival.
This trial tests a vaccine (STEMVAC) given with your standard hormone therapy or chemotherapy. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer who are already on certain treatments. The goal is to see if adding the vaccine can help control the cancer better.
This Phase 2 trial studies pembrolizumab (an immune-boosting cancer medicine) alone or with an added investigational UV1 vaccine in people with advanced non-small cell lung cancer. It aims to see whether adding the vaccine improves safety and effectiveness, especially in tumors with high PD-L1 levels.
Hear when a new Stage IV Lung Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.